News & Media
Press Releases
Amolyt Pharma Presents First Clinical Data for AZP-3601, its Parathyroid Hormone Analog for Hypoparathyroidism, at the Endocrine Society’s Virtual Annual Meeting (ENDO 2021)
Download a PDF copy of this press release: EN FR Data from first 4 cohorts of the single ascending dose (SAD) study show that AZP-3601 …
Amolyt Pharma to Present Preliminary Phase 1 Data on AZP-3601 for Hypoparathyroidism and Additional Preclinical Data on AZP-3404 at ENDO 2021
Download a PDF copy of this press release: EN FR Four abstracts accepted as poster presentations for the Endocrine Society’s Annual Meeting LYON, France, and …
Amolyt Pharma Receives Orphan Drug Designation for AZP-3601 for the Potential Treatment of Hypoparathyroidism
Amolyt Pharma Receives Orphan Drug Designation for AZP-3601 for the Potential Treatment of Hypoparathyroidism Download a PDF copy of this press release: EN FR Lyon, …
Presentations
- All PRESENTATIONS
- AZP-3404
- AZP-3601
- All PRESENTATIONS
- AZP-3404
- AZP-3601
Upcoming events
Date: May 17-19, 2021
Date: May 17-20, 2021 (Virtual)
Date: May 22-25, 2021 (Virtual)
Date: May 26-29, 2021 (Virtual)
Date: June 1, 2021
Date: September 29 – October 3, 2021 (Virtual)
Date: October 1-4, 2021 (Toronto)
Date: October 13-16, 2021 (Le Havre)
Date: October 19-22, 2021 (Denver, CO)
Date: November 2-7, 2021 (San Diego, CA)
Social Updates
TWITTER